Dr. Igor Rybinnik, MD

Dr. Rybinnik practices at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health.

Dr. Rybinnik's NPI, 1710146386, was assigned on June 8, 2008. Dr. Rybinnik graduated from State University of NY Upstate Medical University in 2006. Dr. Rybinnik holds New Jersey license 25MA09328200.

Dr. Rybinnik's primary practice is Robert Wood Johnson University Hospital, at One Robert Wood Johnson Place, New Brunswick, NJ 08901 in Middlesex County. The practice phone is (732) 828-3000. Dr. Rybinnik also practices at Robert Wood Johnson University Hospital - New Brunswick, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901.

Dr. Rybinnik's primary practice is Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health. The medical group on file is Rutgers-RWJ Scleroderma Program. Dmand AI also links Dr. Rybinnik to 1 more group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rybinnik practices, 3 sites in all. Vendor and product names are available with a free account.

Vascular neurology is Dr. Rybinnik's primary specialty in the NPI Registry, under taxonomy code 2084V0102X. Dmand AI has Dr. Rybinnik's licenses on file in 2 states: New Jersey and New York.

CMS data shows 491 Medicare services from Dr. Rybinnik across 7 procedure codes in 2024, for 186 Medicare patients. Medicare paid $39,804 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 186 Medicare patients who saw Dr. Rybinnik in 2024. The largest group is 75 to 84, with 83 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rybinnik's median patient age at 74, with 46% women.

In 2024, Dr. Rybinnik wrote 308 Medicare Part D claims for 70 patients. 90% of them were for generic drugs. CMS names the drug for 230 of them, across 8 drugs with 11 or more claims each, at $12,837 in total drug cost. In 2023, CMS named 126 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Rybinnik for performance year 2024, reported as part of a group. Dr. Rybinnik accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Rybinnik, published from 2013 to 2024. 2020 was the busiest year, with 5. The most frequent topics are Stroke, Tissue Plasminogen Activator and Brain Ischemia. Dr. Rybinnik has published most often in J Stroke Cerebrovasc Dis. Dr. Rybinnik's most frequent co-authors are Brett L. Cucchiara, MD, Scott E. Kasner, MD and Benson Dale Deverett, MD.

Dmand AI links Dr. Rybinnik to 1 clinical trial. Conditions studied include Cerebral Hemorrhage and Intracranial Hemorrhages.

CMS Open Payments shows 5 general payments to Dr. Rybinnik from 4 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 100% of the total. Stryker Corporation paid the most, $130.

Dr. Rybinnik graduated from State University of NY Upstate Medical University in 2006.